Novartis Kisqali: longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer

 -- MONALEESA-3 median overall survival (OS) results of 53.7 months

      underscore that Kisqali offers more life to postmenopausal women with 
      HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit 
      demonstrated for premenopausal women as shown in MONALEESA-71,2 
 
   -- The relative risk reduction of death by 36% in the MONALEESA-3 first-line 
      (1L) postmenopausal population highlights that Kisqali is the only 
      CDK4/6i with proven OS for 1L in combination with fulvestrant1 
 
   -- Time to chemotherapy was delayed to 4 years (48.1 months) in 
      postmenopausal women taking Kisqali in combination with fulvestrant 
      compared to 2.4 years (28.8 months) for women receiving fulvestrant only1 
 
   -- MBC takes a life in the US approximately every 12 minutes, creating an 
      urgent need for treatment proven to extend life while preserving quality 
      of life3-6 

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Press-Release-nbsp-Novartis-Kisqali-R-reports-longest-median-overall-survival-in-postmenopausal-H-35500199/